Cardiff Oncology Inc expected to post a loss of 27 cents a share - Earnings Preview

Cardiff Oncology

29/10/2024 11:22

* Cardiff Oncology Inc  CRDF.OQ   CRDF.O  is expected
to show a
fall in quarterly revenue when it reports  results on October 31
(estimated) for the period ending September 30 2024
    * The San Diego California-based  company is expected to
report a
43.3% decrease in revenue to $80 thousand from $141 thousand a
year ago, according to the mean estimate from 5 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Cardiff Oncology Inc is
for a
loss of 27 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is 8.00​, above​ its last closing price of $2.99. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024              -0.25      -0.26     Missed  -5.1
 Jan. 1 2024   -0.25       -0.25      -0.22     Beat    11.1
 Dec. 31 2023  -0.27       -0.28      -0.21     Beat    24.3​
 Sep. 30 2023  -0.28       -0.28      -0.22     Beat    22.8
 ​​Jan.        -0.28       -0.26      -0.25     Beat    3.5
 1 0001                                                 
 Mar. 31 2023  -0.22       -0.23      -0.25     Missed  -10.6​
 Jan. 1 0001   -0.22       -0.23      -0.20     Beat    14.9
 Jan. 1 0001   -0.27       -0.26      -0.20     Beat    24.2
 This summary was machine generated October 29 at 11:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)